Sionna Therapeutics, Inc. (SION)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Michael Cloonan M.B.A. | President, CEO & Director | 784.59k | -- | 1972 |
| Ms. Elena H. Ridloff C.F.A. | CFO & Head of Corporate Development | 647.92k | -- | 1980 |
| Dr. Charlotte McKee M.D. | Chief Medical Officer | 647.92k | -- | 1965 |
| Dr. Greg Hurlbut Ph.D. | Co-Founder & Senior VP of Discovery Research | -- | -- | -- |
| Dr. Mark Munson Ph.D. | Co-founder & Senior VP of Medicinal Chemistry | -- | -- | -- |
| Ms. Meghan Bagshaw | Vice President of Programs, Portfolio & Operations | -- | -- | -- |
| Mr. Andy Chu | Vice President of Information & Technology | -- | -- | -- |
| Ms. Jennifer Fitzpatrick J.D. | Chief Legal Officer | -- | -- | 1977 |
| Ms. Vanya Sagar | Chief People Officer | -- | -- | 1976 |
| Ms. Mara Furlow M.S. | Senior Vice President of Global Regulatory Affairs & Quality | -- | -- | -- |
Sionna Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 48
Description
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Upcoming Events
August 19, 2025 at 12:30 PM UTC - September 3, 2025 at 12:30 PM UTC
Sionna Therapeutics, Inc. Earnings Date
Recent Events
February 4, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
January 24, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
January 17, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission